MKM Partners Raises Eli Lilly and Price Target to $65.00
The firm currently has a "neutral" rating on the stock. MKM Partners' price target would indicate a potential downside of 0.41% from the stock's previous close.
Eli Lilly and major shareholder Unloads $13,601,700 in Stock
Eli Lilly and major shareholder Lilly Endowment Inc unloaded 210,000 shares of Eli Lilly and stock on the open market in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $64.77, for a total value of $13,601,700.00.
Takeda Responds to Judgment in Diabetes Drug Case
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v.
Eli Lilly and Given Consensus Recommendation of "Buy" by Brokerages
Eli Lilly and has earned an average recommendation of "Buy" from the twenty-two analysts that are presently covering the stock, Analyst Ratings Network.com reports .
Eli Lilly and Receives Average Recommendation of "Buy" from Analysts
Eli Lilly and has received an average recommendation of "Buy" from the twenty-two analysts that are currently covering the stock, ARN reports .
Eli Lilly and Coverage Initiated by Analysts at Deutsche Bank
The firm set a "buy" rating on the stock. Several other analysts have also recently commented on the stock.